Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal) (TA1125)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2026
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 August 2022
Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2008